Breast Cancer

Despite increased awareness and a near-80% compliance rate for annual screening, breast cancer remains a major threat for women around the world, with 1 in 8 women estimated to develop breast cancer at some point throughout their lifetime. 

The genTRU-breast™ liquid biopsy program, designed for targeted screening and confirmatory diagnosis of breast cancer, is positioned to rule more patients with an elevated risk of developing breast cancer and/or those with inconclusive radiology into evidence-based imaging and care pathways earlier (e.g., genTRU B-EDT, early detection testing) and to eliminate unnecessary invasive biopsies for patients with suspicious nodules discovered incidentally and/or through routine screening (e.g., genTRU B-PID, post-imaging diagnosis). 

The patent-pending genTRU-breast™ program has been extensively validated, with our team of internal and external partners successfully completing 35 R&D studies, including 28 independent cross-cohort validations, across 5 independent patient cohorts and 357 case-control clinical specimens, with strong reproducibility and best-in-class diagnostic sensitivity and specificity achieved in all studies.